Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Helping Patients With HR+/HER2- Breast Cancer Access Abemaciclib

September 6th 2023

Experts explain the challenges patients with HR+/HER- breast cancer face in accessing abemaciclib for treatment and the options available such as patient assistance programs for high co-pays.

Dr Armaghani on the Investigation of De-Escalated Treatment Approaches in TNBC

September 5th 2023

Avan Armaghani,cdiscusses the feasibility of de-escalating treatment in triple-negative breast cancer, as well as planned or ongoing research investigating this approach in the neoadjuvant and metastatic settings.

Retrospective Data Show Aggressive Axillary Surgery Is Not Associated With Improved Outcomes in Select Patients With Breast Cancer

September 2nd 2023

Raymond Mailhot Vega, MD, MPH, delves into the rationale for exploring the outcomes of patients who underwent axillary surgery or sentinel lymph node biopsy, explained the implications of these findings, and detailed what eventual data from the phase 3 Alliance A011202 could mean for the breast cancer treatment paradigm.

Dr Quiroga on the Emergence of HER2-Low in Breast Cancer

September 1st 2023

Dionisia Quiroga, DO, PhD, discusses the emergence of the HER2-low categorization in breast cancer as well as current treatment options for patients with HER2-low disease.

Dr Kesireddy on the Future Use of Capivasertib Plus Fulvestrant in HR+/HER2– Breast Cancer

September 1st 2023

Meghana Kesireddy, MBBS, discusses the pending FDA approval of the AKT inhibitor capivasertib plus the selective estrogen receptor degrader fulvestrant in patients with hormone receptor–positive, HER2-negative breast cancer.

Dr Gatti-Mays on Updated Biomarker Data From the NeoPACT Study in TNBC

August 31st 2023

Margaret E. Gatti-Mays, MD, MPH, FACP, discusses updated biomarker data from the phase 2 NeoPACT trial of neoadjuvant chemoimmunotherapy in triple-negative breast cancer.

Considerations for Chemotherapy Dosing in Patients With HR+/HER- Breast Cancer

August 30th 2023

The panel discusses the importance of careful chemotherapy dosing and management of side effects for patients with HR+/HER- breast cancer, including the use of cooling and compression gloves to prevent peripheral neuropathy.

Clinical Scenario: A 60-Year-Old Woman With Newly Diagnosed Breast Cancer

August 30th 2023

Naomi Dempsey, MD, presents the clinical scenario of a 60-year-old woman with newly diagnosed HR+/HER- breast cancer to the panel for discussion.

NDA Submission Planned for EA-114 in Metastatic Breast Cancer Following Positive Type C Meeting With FDA

August 30th 2023

The FDA and Eagle Pharmaceuticals have agreed on the next steps for the development of EA-114, an estrogen receptor antagonist and novel formulation of fulvestrant used in the treatment of postmenopausal women with breast cancer.

TROPiCS-02 Data Reinforce Role of Sacituzumab Govitecan as a SOC in HR+ Breast Cancer

August 29th 2023

Sara M. Tolaney, MD, MPH, highlights updated survival and safety data seen with sacituzumab govitecan in patients with hormone receptor–positive, HER2-negative breast cancer; underscores how Trop-2 and HER2 testing is not necessarily needed for this agent in this population at this time; and shares how ongoing efforts are exploring the utilization of this agent earlier in the treatment course.

Dr McKenzie on Updates to ASCO Treatment Guidelines in Metastatic Breast Cancer

August 28th 2023

Andrew McKenzie, PhD, discusses the updates to the ASCO clinical practice guidelines for biomarker testing in patients with metastatic breast cancer.

Dr. Ramaswamy on the Real-World Data Implications of Palbociclib in HR-Positive Breast Cancer

August 24th 2023

Bhuvaneswari Ramaswamy, MD, discusses the importance of real-world data when considering the efficacy of the CDK 4/6 inhibitor palbociclib in hormone receptor–positive breast cancer.

The Future of HER2+ Breast Cancer Treatment

August 24th 2023

Panelists wrap up their discussion on HER2+ breast cancer by summarizing the most exciting recent advances in the field and their hopes for the future of treatment.

Dr Hamilton on the Use of ADCs in Breast Cancer

August 23rd 2023

Erika P. Hamilton, MD, discusses the use and sequencing of antibody-drug conjugates in patients with hormone receptor-positive/HER2-negative and HER2-low breast cancer.

Looking Towards The Future of HR+/HER2- Breast Cancer

August 22nd 2023

The expert panel discusses ongoing research and offers closing thoughts on the future of HR+/HER2- breast cancer treatment.

Dr Tarantino on the Use of ADCs in HR+ Breast Cancer

August 22nd 2023

Paolo Tarantino, MD, discusses the use of antibody drug conjugates in patients with hormone receptor-positive breast cancer.

Practical Considerations for ADC Selection in HR+/HER2- mBC

August 22nd 2023

Panelists share clinical insight into how to approach treatment selection among ADCs in HR+/HER2- metastatic breast cancer both now and in the future, given the currently available options and additional ADCs in development.

Novel ADCs Must Keep Up With Moving Targets in Metastatic Breast Cancer

August 22nd 2023

Barbara Pistilli, MD, discusses the mechanism of action of novel ADCs, the ways in which ADC targets in breast cancer can change over time, and how future research may pave the way for individualized treatment with this class of agents.

Barriers to Optimal Care in Patients With HR+/HER- Breast Cancer

August 22nd 2023

Key opinion leaders detail various barriers to optimal care for patients with HR+/HER2- breast cancer, including transportation issues, financial difficulties, lack of family support, and challenges in coordinating care among different medical specialists.

Importance of Multidisciplinary Care for Patients With HR+/HER- Breast Cancer

August 22nd 2023

A panel of experts explains the importance of a multidisciplinary team in treating HR+/HER2- breast cancer to ensure comprehensive and coordinated care throughout the patient's journey.